Axa S.A. Boosts Stock Position in Pfizer Inc. $PFE

Axa S.A. grew its position in Pfizer Inc. (NYSE:PFE) by 13.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,518,659 shares of the biopharmaceutical company’s stock after purchasing an additional 296,001 shares during the period. Axa S.A.’s holdings in Pfizer were worth $61,052,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Westbourne Investments Inc. purchased a new stake in Pfizer in the first quarter valued at approximately $2,411,000. Bourne Lent Asset Management Inc. grew its stake in shares of Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after buying an additional 18,200 shares in the last quarter. Strs Ohio purchased a new stake in shares of Pfizer in the 1st quarter valued at $49,968,000. IFM Investors Pty Ltd lifted its stake in Pfizer by 3.8% during the 2nd quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock worth $27,322,000 after acquiring an additional 41,263 shares in the last quarter. Finally, Ossiam boosted its holdings in Pfizer by 71.2% during the 2nd quarter. Ossiam now owns 5,650,573 shares of the biopharmaceutical company’s stock valued at $136,970,000 after acquiring an additional 2,349,058 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on PFE shares. Scotiabank started coverage on shares of Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Bank of America increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a research note on Wednesday, November 5th. Finally, Guggenheim increased their price objective on Pfizer from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, November 24th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $28.39.

Pfizer Stock Performance

Shares of PFE stock opened at $25.36 on Wednesday. The company has a market cap of $144.16 billion, a P/E ratio of 14.74 and a beta of 0.46. The firm has a fifty day moving average price of $25.21 and a 200 day moving average price of $24.73. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 7th were paid a dividend of $0.43 per share. The ex-dividend date was Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s payout ratio is presently 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.